Research prototype, not medical advice.

Lonafarnib reduces mortality in children with progeria (cohort study); FDA-approved in 2020.

Confidence
Established
Level of evidence
Approved by a health authority
Observed in
Human
Mission
Map of aging (12 hallmarks)
Concepts
Genomic instabilityLonafarnibHutchinson-Gilford progeria syndrome

What the sources say

Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).

DirectionSourceWhere in the articleStatus
Supports Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome
Gordon et al. · JAMA 2018
— Verified